Village Farms heads into its third-quarter report with a peculiar setup: the business appears to be getting better, yet Wall Street expects earnings to shrink. The explanation lies in the calendar. A year ago, seasonal greenhouse yields pushed cannabis gross margin to an unusually high 56%, and that strong comparison now sits squarely in front of a company that management insists is still accelerating. The question for this report is whether the European export story can carry the quarter through a demanding comparison.

Consensus calls for earnings of $0.05 per share on revenue of about $64.4 million. That would be a 37.5% decline from the $0.08 earned a year earlier and a 3.6% dip in sales from $66.7 million. It would also be slightly below the $0.06 posted last quarter, while revenue would be essentially flat sequentially. The company has not offered formal numerical guidance, so the Street's modest bar reflects analysts' own caution rather than a management target. It amounts to a forecast of a mild contraction, not a collapse.

The prior call gave investors plenty to measure. International exports rose 74% from a year earlier and 43% sequentially to a record, driven by share gains in Germany, where Village Farms claims the widest pharmacy distribution of any cultivator and several top-selling strains. Cannabis gross margin reached 51%, well above management's stated long-term range of 30% to 40%, and cannabis adjusted EBITDA hit a record $15.3 million. Validation this quarter would mean another sequential rise in export sales, even if the percentage growth keeps cooling off a larger base, and gross margin holding near the high 40s or better despite the tough comparison. Management also signaled entry into new European jurisdictions in the back half of the year, so any evidence of first shipments there would strengthen the case that growth is broadening beyond Germany.

Capacity is the second test. The Kroningen Phase II facility in the Netherlands came online last quarter after an earlier delay and is supposed to ramp toward full output by early next year. Meanwhile, conversion of the second half of Delta II began September 1, part of a path toward roughly 160 metric tons of annual capacity. Investors should look for confirmation that both projects remain on schedule and that the Delta conversion did not disrupt production more than expected. Netherlands pricing softness, which management acknowledged as competitors ramp, is a swing factor worth watching too.

Cash flow may be the most underappreciated item. Operating cash flow in cannabis fell sharply last quarter as Canadian corporate tax payments and longer export payment terms absorbed working capital. Management nevertheless pointed to stronger free cash flow and a growing cash balance in the second half, building on $73 million of cash after a $15 million equity placement. If cash rises from that level, the tax drag looks manageable. If it slips, the export growth story starts to look more expensive than advertised. Rising SG&A, which climbed to 28% of cannabis sales, also needs to stabilize.

The market has been receptive. Shares have gained 7.8% since the last report while the S&P 500 fell 2.2%, and sentiment has edged slightly less bearish. Still, at $2.50 the stock sits below its 200-day moving average of $2.69 and well off its post-earnings high of $3.20, suggesting enthusiasm has faded from its peak. Ultimately, this report hinges on whether export momentum and margin discipline can show through a difficult seasonal comparison while cash finally begins to build, as management promised.